CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
ZD6474 (vandetanib)drug
Likely dose
ZD6474 (vandetanib) oral once dailyAI-extracted
Key inclusion· 3
  • ✓Histologically or cytologically confirmed locally advanced or metastatic hereditary medullary thyroid cancer
  • ✓One or more measurable lesions
  • ✓Signed informed consent
Key exclusion· 4
  • ✕Brain metastases or spinal cord compression
  • ✕Prior chemotherapy and/or radiation therapy
  • ✕Participation in other trials within 30 days
  • ✕Specific heart problems

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00098345
NCT00098345Phase 2Completed
CompareCT.gov

An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.

Genzyme, a Sanofi Company·interventional·Posted Dec 8, 2004·Updated May 7, 2018

In Brief

A Phase 2 clinical trial evaluating ZD6474 (vandetanib) for Thyroid Cancer. Completed, enrolled 40 participants across 6 sites in 2 countries.

Detailed Summary

The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Cancer
CountriesFrance, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 8, 2004
Enrollment StartNov 1, 2004
Primary CompletionFeb 1, 2008
Study CompletionApr 19, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 21.6 years ago

Interventions

ZD6474 (vandetanib)drug

oral once daily tablet